Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

被引:130
作者
Fransen, Signe [1 ]
Gupta, Soumi [1 ]
Danovich, Robert [2 ]
Hazuda, Daria [2 ]
Miller, Michael [2 ]
Witmer, Marc [2 ]
Petropoulos, Christos J. [1 ]
Huang, Wei [1 ]
机构
[1] Monogram Biosci, San Francisco, CA 94080 USA
[2] Merck Res Labs, West Point, PA USA
基金
美国国家卫生研究院;
关键词
TREATMENT-EXPERIENCED PATIENTS; PROTEIN IN-VITRO; HIV-1; INTEGRASE; STRAND TRANSFER; DIKETO DERIVATIVES; DNA INTEGRATION; RESISTANCE; INHIBITOR; MUTATIONS; ORGANIZATION;
D O I
10.1128/JVI.01168-09
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The human immunodeficiency virus type 1 (HIV-1) integrase mutations N155H and Q148R(H)(K) that reduce susceptibility to the integrase inhibitor raltegravir have been identified in patients failing treatment regimens containing raltegravir. Whether these resistance mutations occur individually or in combination within a single virus genome has not been defined, nor do we fully understand the impact of these primary mutations and other secondary mutations on raltegravir susceptibility and viral replication capacity. To address these important questions, we investigated the raltegravir susceptibility and replication capacity of viruses containing mutations at positions 155 and 148 separately or in combination with secondary mutations selected in subjects failing treatment regimens containing raltegravir. Clonal analysis demonstrated that N155H and Q148R(H)(K) occur independently, not in combination. Viruses containing a Q148R(H)(K) mutation generally displayed larger reductions in raltegravir susceptibility than viruses with an N155H mutation. Analysis of site-directed mutants indicated that E92Q in combination with N155H resulted in a higher level of resistance to raltegravir than N155H alone. Viruses containing a Q148R(H) mutation together with a G140S mutation were more resistant to raltegravir than viruses containing a Q148R(H) mutation alone; however, viruses containing G140S and Q148K were more susceptible to raltegravir than viruses containing a Q148K mutation alone. Both N155H and Q148R(H)(K) mutations reduced the replication capacity, while the addition of secondary mutations either improved or reduced the replication capacity depending on the primary mutation. This study demonstrates distinct genetic pathways to resistance in subjects failing raltegravir regimens and defines the effects of primary and secondary resistance mutations on raltegravir susceptibility and replication capacity.
引用
收藏
页码:11440 / 11446
页数:7
相关论文
共 27 条
[1]   HIV-1 integrase: Structural organization, conformational changes, and catalysis [J].
Asante-Appiah, E ;
Skalka, AM .
ADVANCES IN VIRUS RESEARCH, VOL 52, 1999, 52 :351-369
[2]   RETROVIRAL DNA INTEGRATION DIRECTED BY HIV INTEGRATION PROTEIN INVITRO [J].
BUSHMAN, FD ;
FUJIWARA, T ;
CRAIGIE, R .
SCIENCE, 1990, 249 (4976) :1555-1558
[4]   Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy [J].
Charpentier, C. ;
Karmochkine, M. ;
Laureillard, D. ;
Tisserand, P. ;
Belec, L. ;
Weiss, L. ;
Si-Mohamed, A. ;
Piketty, C. .
HIV MEDICINE, 2008, 9 (09) :765-770
[5]   Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection [J].
Cooper, David A. ;
Steigbigel, Roy T. ;
Gatell, Jose M. ;
Rockstroh, Jurgen K. ;
Katlama, Christine ;
Yeni, Patrick ;
Lazzarin, Adriano ;
Clotet, Bonaventura ;
Kumar, Princy N. ;
Eron, Joseph E. ;
Schechter, Mauro ;
Markowitz, Martin ;
Loutfy, Mona R. ;
Lennox, Jeffrey L. ;
Zhao, Jing ;
Chen, Joshua ;
Ryan, Desmond M. ;
Rhodes, Rand R. ;
Killar, John A. ;
Gilde, Lucinda R. ;
Strohmaier, Kim M. ;
Meibohm, Anne R. ;
Miller, Michael D. ;
Hazuda, Daria J. ;
Nessly, Michael L. ;
DiNubile, Mark J. ;
Isaacs, Robin D. ;
Teppler, Hedy ;
Nguyen, Bach-Yen .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :355-365
[6]  
Da Silva D, 2008, ANTIVIR THER, V13, pA14
[7]   Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients [J].
DeJesus, Edwin ;
Berger, Daniel ;
Markowitz, Martin ;
Cohen, Calvin ;
Hawkins, Trevor ;
Ruane, Peter ;
Elion, Richard ;
Farthing, Charles ;
Zhong, Lijie ;
Cheng, Andrew K. ;
McColl, Dainian ;
Kearney, Brian P. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (01) :1-5
[8]   IDENTIFICATION OF DISCRETE FUNCTIONAL DOMAINS OF HIV-1 INTEGRASE AND THEIR ORGANIZATION WITHIN AN ACTIVE MULTIMERIC COMPLEX [J].
ENGELMAN, A ;
BUSHMAN, FD ;
CRAIGIE, R .
EMBO JOURNAL, 1993, 12 (08) :3269-3275
[9]   HIV-1 DNA INTEGRATION - MECHANISM OF VIRAL-DNA CLEAVAGE AND DNA STRAND TRANSFER [J].
ENGELMAN, A ;
MIZUUCHI, K ;
CRAIGIE, R .
CELL, 1991, 67 (06) :1211-1221
[10]   HIV integrase structure and function [J].
Esposito, D ;
Craigie, R .
ADVANCES IN VIRUS RESEARCH, VOL 52, 1999, 52 :319-333